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During the past eight months, more than twenty 
patients at the University of Colorado have been 
treated with heterologous antilymphocyte globulin 
(ALG),  prepared from the serum of horses which 
had been immunized against lymphocytes from the 
thymus, lymph nodes, and spleens of fresh human 
cadavers. Although the clinical experience with this 
immunosuppressive agent has admittedly been lim- 
ited, the observations made so far provide hope that 
ALG can be used with benefit and with relative 
safety after homotransplantation of kidneys or other 
organs in man. 
As reviewed by Medawar in Chapter 32, there has 
been intermittent interest in heterologous antilym- 
phocyte sera (ALS) for almost seventy years. How- 
ever, the notion that ALS or its derivatives might be 
used for the treatment of patients stemmed from the 
historic report of WoodruffL"n 1963. Since that 
time, numerous other important publications have 
appeared dealing with various features of the prep- 
aration, mechanism of action, testing, and purifica- 
tion of antilymphocyte products for use in 
1 3 , l S - I i  rats,10,2S guinea pigs,l?,22 dogS1-3,7,0,11,14,18,20 
and humans.Q,zl,2z 
Therapeutic Protocol 
The regimen used was based upon guidelines pro- 
vided by animal experimentation and included the 
following considerations. First, although ALS or 
ALG have powerful immunosuppressive qualities, 
these do not invariably prevent homograft rejection, 
a point particularly well demonstrated with renal or 
liver homotransplantations in the outbred canine 
population. Secondly, they have a variable additive 
effect when combined with various . anti- 
metabolites,"zl steroids,l"r, under carefully de- 
fined conditions, with total body irradiation1" by 
far the most striking synergism in animals has been 
seen with the combination of steroids and ALS. 
Third, ALS therapy in animals has a significant 
risk from anaphylaxis and from foreign protein ne- 
phritis,g although this is apparently less than with 
the use of normal horse serum. Fourth, the most 
effective program of therapy includes treatment be- 
fore as well as after tran~p1antation.l"~~ Finally, 
an immunosuppressive effect is not dependent upon 
the production of lymph~penia . ' , ' , ' " .~~ 
For these reasons, ALG was used clinically only as 
an adjuvant agent added to therapy with azathio- 
prine and prednisone. For twenty newly operated 
cases, it was usually started five to six days in ad- 
vance of surgery, continued daily for ten to fourteen 
days afterward, then every other day for two weeks, 
two times a week for two months, and once a week 
for a final month (Fig. 1 ) . 
The ALG used was an ammonium sulphate pre- 
cipitate consisting principally of gamma G globulin, 
but with components of T-equine and beta globulin. 
Various batches had leuko-agglutinating titers of 
1 :4000 to 1:32000 and a protein concentration of 
4.6 to 9.3 Gm. per cent. Doses were 1 to ,5 ml., 
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Fig. 1.-Course of a patient who received ALG before and after renal homotrans- 
plantation. The homograft was provided by a brother. There has never been a rejection. 
The prednisone was started after forty days because of the increases in hemagglutinin 
and precipitin titers. Note the subsequent decline in titers despite continuation of the 
globulin injections. (Courtesy J.  and A. Churrhill, Ltd., London). 
depending upon the titer of the material and the 
weight of the patients. The intramusc~llar route was 
used. During the course of globulin administration, 
the doses per week ranged from 14 to 50 mg./Kg. at 
the beginning and 2 to 6 mg.1 Kg, at the end. 
The effect of ALG therapy upon the peripheral 
white cells was unpredictable during the period of 
pieoperative treatment when only this immunosup- 
pressive agent was being used. The per cent of lym- 
phocytes was decreased (Fig. 2 ) .  There was, how- 
ever, an accompanying leukocytosis, with the result 
that the peripheral lymphocyte count was not usually 
significantly reduced ( Fig. 2 ) .  
Nevertheless, a profound effect upon the immuno- 
logic reactivity of the host was evident during this 
period. A number of patients were studied by Drs. 
Frank Brunstetter and Henry N. Claman before the 
onset of therapy for cutaneous hypersensitivity to 
Candida albicans, tuberculin. mumps, histoplasmin, 
and Trichophyton. In five instances, one or the other 
of these was positive, and in each, the skin test had 
become negative when redetermined after three, or 
four days of ALC therapy. There were no examples 
of failure of a skin reaction to disappear. These re- 
sults indicate that the ALG being used prevented 
the expression of pre-existing delayed 11ypel.sensitiv- 
ity reactions. 
In all freshly operated cases, azathioprine was 
started the day before transplantation and continued 
indefinitely thereafter. Prednisone treatment was in- 
stituted either in the event of rejection, or because 
of the development of high precipitin titers against 
horse protein, or in a number of later cases prophy- 
lactically to forestall either of the above complica- 
tions. In all instances, it was attempted to use the 
smallest possible quantities of steroids. Actinomycin 
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Fig. 2.-The effect of antihuman-lymphoid globulin in six patients treated daily for 
five days before renal homotransplantation. "Stabs" refer to nonsegmented neutrophiles. 
(Courtesy Surg. Gynec. Obstet.) 
Fig. 3.-Mortality in patients treated with adjuvant ALG compared to that in three 
preceding series of consanguineous transplantations carried out in Denver. The numbers 
in the ALG series refer to the patients at risk at the indicated times. (Courtesy J. and A. 
Churchill, Ltd., London.) 
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C and local homograft irradiation wcre used irregu- 
larly. 
In four other cases, a similar course of ALG was 
added from five to eleven months after operation for 
the treatment of patients with late failing homo- 
grafts. In these cases, deterioration of renal function 
had not been preventable when prednisone doses 
smaller than 0.5 to 1.7 mg./Kg. per day had been 
used. After beginning globulin therapy, steroid dos- 
ages were then rapidly attenuated. 
New Cases 
MORTALITY 
There has only been one death in these twenty 
cases (Fig. 3) ,  resulting from a technical acci- 
dent. The first eight patients have now been fol- 
lowed for six and a half to seven and a half months, 
the next eight for three to five months, and the last 
four for six to eight weeks. In nineteen of the twenty 
cases, the homografts were provided by blood rela- 
tives; parents for five, siblings for thirteen, and a 
maternal uncle for the other. The twentieth patient 
received. a cadaver graft. Analysis of lymphocyte 
antigens was performed by Dr. Paul Terasaki in these 
donor-recipient pairs, but no attempt was made to 
obtain a good antigen match; the pairings were 
therefore on an essentially random basis. The mortal- 
ity of the test series was compared to that obtained 
in the past with three successive groups of patients 
treated at the University of Colorado Medical Center 
with homografts from consanguineous donors. The 
death rate was higher in each of these retrospective 
control series during the early postoperative months 
(Fig. 3 ) .  
IMMUNOSUPPRESSION 
The probable reason for the improvement in sur- 
vival was the reduction which was possible in the 
quantity of the standard immunosuppressive drugs 
azathioprine and prednisone. During the period 
when the original retrospective control series were 
being compiled, there had been an increasing con- 
servatism with use of azathioprine in an attempt to 
avoid the bone marrow depression which in earlier 
days had been the chief cause of death. This trend 
continued into the ALG cases (Fig. 4 ) .  This infor- 
mation is shown graphically as the average daily 
dose for the first 105 postoperative days for patients 
of the three retrospective groups who lived this long, 
compared to the first ten ALG patients. Incllision in 
the study was contingent upon survival for the 
period of study; thereby fourteen cases were elim- 
inated from the retrospective series but none among 
the first ten ALG patients. 
The ability to treat with reduced doses of steroids 
was even more significant than the decreased quan- 
tities of azathioprine. In the three preceding series, 
the average steroid doses per day were the same for 
Groups 1 and 2, and in Group 3 there had been an 
increase. In contrast, the ALG patients required less 
than half the daily prednisone doses (Fig. 4 ) .  
GROUP I - 23 PATIENTS 
GROUP 2 I2 PATIENTS 
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Fig. 4.-Average daily doses of azathioprine and 
prednisone for the first fifteen postoperative weeks 
in three preceding series of consanguineous homo- 
transplantations done in Denver, compared to the 
doses used for the first ten consecutive patients treated 
with adjuvant ALG. Since inclusion in the study was 
contingent upon survival for this period, nine, two, 
and three other patients from the retrospective con- 
trol series were eliminated by their early death; such 
a correction was unnecessary in the ALG cases. Note 
that the ALG-treated patients received reduced quan- 
tities of the "standard" immunosuppressive agents. 
(Courtesy J. and A. Churchill Ltd., London.) 
FUNCTION 
The reduction in doses of standard immunosup- 
pressive agents was not at the sacrifice of renal func- 
tion. The average BUN'S and creatinine clearances 
in the ten ALG-treated patients were better in all 
but one of the retrospective control groups. It will be 
recalled that more than a dozen patients who died 
during this 105 day period of analysis and who gen- 
erally had the poorest function were excluded, thus 
insuring the retention of only the best cases; all of 
the first ten cases in the ALG series were included. 
The excellent showing of the test cases was therefore 
i11 spite of this bias. 
By pooling the functions as described above, it 
would be possible to conceal trends in function for 
either the control or test series. To obtain a more 
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dynamic view of the postoperative events, creatinine 
clearances were obtained on a weekly basis for the 
patients in each of the control series who lived at 
least twenty-two weeks, and these were compared to 
the first eight consecutive patients in the ALG series. 
The creatinine clearances in all groups were initially 
variable. After two months, however, the ALG- 
treated patients showed an improvement which dis- 
tinguished them from the members of the other 
series (Fig. 5 ) ,  and which was sustained for at least 
the first months after discontinuance of the ALG 
course. Thus, as ALG therapy was being reduced 
and finally stopped, the continuing high quality 
of renal function made it unnecessary to make up- 
ward adjustments in the other drugs. 
IIC 
100 
Late Cases 
These four patients had poor homograft function 
when ALG therapy was started. In two cases, it 
was possible to reduce prednisone from 1.3 and 
1.0 mg./Kg./day, respectively, to 0.4 and 0.3 mg. 
without deterioration in renal function. The course of 
one of these patients is shown in Figure 6. A series 
of disasters had followed transplantation including 
pancreatitis, disruption and repair of a ureteroureter- 
ostomy, a left paravertebral gutter abscess, massive 
wound hemorrhage, and complete heart block which 
had necessitated transvenous insertion of a cardiac 
pacemaker. The prognosis was worsened by the fact 
that all attempts to reduce prednisone below 40 to 
GROUP I - 2 3  PATIENTS ( 2 3 / 3 2 )  
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Fig. 5.-Relation of average prednisone doses to creatinine clearances during the 
.st twenty-two weeks for the first eight ALG-treated patients, compared to comparable 
~ta in the three retrospective control series. Note that the patients in the ALG group 
ceived the smallest quantities of steroids, and that they ultimately had the highest 
erage clearances. (Courtesy J. and A. Churchill, Ltd.. London.) 
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Fig. 6.-Course of patient with a failing renal homograft who was treated late with 
antilymphoid globulin. During the first four postoperative months, there were several 
potentially lethal postoperative complications which were made more grave by the need 
for heavy steroid therapy. Efforts to reduce the prednisone dosage resulted in deteriora- 
tion of renal function. After institution of antilymphoid globulin therapy, renal functions 
slightly improved despite a rapid decrease of the steroid doses, and this has been 
sustained since completion of the ALG course. (Courtesy J. and A. Churchill, Ltd., 
London. ) 
60 mg./day caused deterioration of graft function. 
After starting ALG, it was possible to reduce pred- 
nisone to 15 mg. per day. The BUN fell and the 
creatinine clearance rose slightly. The other success- 
fully treated case was similar. 
One of the other patients, whose creatinine clear- 
ance was 3 to 5 ml./min. at the time ALG was 
started, died of viral pneumonitis and heart failure. 
All therapy was eventually stopped for the fourth 
patient who ultimately had a second trar~splantation 
several months later during retreatment with ALG. 
The second course of globulin injections was well 
tolerated. Further details of these cases are pub- 
lished elsewhere.2' 
Toxicity of ALG 
PAIN 
All patients had pain at the site of injection, 
which usually reached a peak in two to six hours. It 
was particularly intense with the first few injections, 
sometimes requiring narcotics. but later it was better 
tolerated. Local swelling, edema, and erythema were 
often noted. 
FEVER 
Hyperpyrexia occurred regularly. Uslially this was 
low grade, but a few patients had temperature rises 
to more than 40" C. 
ANAPHYLAXIS 
Four of the twenty-four patients had reactions 
which were diagnosed as anaphylaxis. These oc- 
curred within a few minutes after injection and 
lasted 1 to 30 min. The patients had air h~inger. 
Three became mildly hypotensive and the fourth was 
transiently hypertensive. Symptomatic treatment was 
given. In three of these four cases, additional sub- 
sequent injections were used for several weeks or 
months. 
Every patient studied had increases in precipitin 
titers against horse serum. These developed from two 
to seven weeks after beginning ALC; therapy (Fig. 
7 )  and were apparently influenced by the way in 
which steroids were used. The greatest titer in- 
creases were in patients who (lid not receive pred- 
nisone until late in their course; here, the addition 
of prednisor~e was followed by a secondary fall in the 
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TIME IN WEEKS 
Fig. 7.-Rises in precipitin titers in the first eight consecutive patients treated with 
antilynlphocyte globulin. The vertical arrows indicate the last dose of ALG given in each 
rase; note that the titers had often begun to decline before this time. (Courtesy J. and A. 
Churchill, Ltd., London.) 
precipitin levels. If steroids were started early, the 
titer rises were later and were sluggish. 
It llas been demonstrated by Dr. Noburu Kashi- 
wagi in our laboratories that most of the precipitins 
in these patients were directed against alpha and 
beta classes of the immunoglobulins. Little activity 
was fo~rnd against the horse gamma G-globulin in 
which an esti~nated 80 per cent of the desired anti- 
bodies are located. Hemagglutinin titers against 
sheep red blood cells, which are a measure of host 
response to Forssman-like antigens in the horse 
serurrr, followed roughly the same pattern as the 
precipitin titers. 
HISTOPATHOLOGIC: STUDIES 
Tlre most encouraging findings came from exam- 
ination of the homograft biopsies which were ob- 
tained in the first eight cases from 108 to 145 days 
after transplantation. There was no evidence what- 
soever of horse protein in the homografts. Sube~ido- 
thelial accumulations of amorphous material were 
present in the glo~nerular capillary walls of six of the 
eight renal homografts biopsied 108 to 145 days 
after homotrmsplantation (Table l ) ,  but only in 
four of the kidneys could any thickening of the base- 
ment membranes be detected by light microscopy. 
The change was focal, and in every glomerulus nor- 
mal loops were present. The density and compact- 
ness of the deposits varied. In one kidney, it was as 
though the lamina densa had been split and a broad 
band of loosely arranged material inserted between 
the two layers. Mesangial cell processes extended 
into a few of the thickened basement membranes. 
There were no subepithelial deposits. 
Immunofluorescence of the six affected kidneys 
demonstrated glomerular capillary basement mem- 
brane localization of Ighl generally in a linear pat- 
tern; one homograft also had glomerular basement 
membrane deposits of RIA and B1C globulin and 
fibrinogen. No localization of IgG or horse globulin 
was detected. 
I11 all the kidneys with glomerular capillary base- 
ment membrane changes, there was some increase in 
the number of mesangial cells and the amount of 
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TABLE 1.-Fluorescent and Electron Microscopic Observations on the Glomeruli of eight Renal 
Homografts in Patients Treated with Horse Antihuman-lymphocyte Globulin 
Patient Electron Microscooy Fluoresce~it Tvlicrosco~v 
Thickening of Glomerular Fusion of Deposits Demonstrated by Fluorescent 
Capillary Basement hlembranes Epithelial Foot Antibody Technique 
Processes 
Horse Complement 
Subendothelial Subepithelial IgM IgG Globulin B1A B1C Fibrinogen 
LD 107 - + 0 f + 0 0 0 0 0 
LD 108 0 0 + 0 0 0 0 0 0 
LD 109 5 0 + + 0 0 0 0 0 
LD 110 + 0 ++ + 0 0 ++ ++ + 
LD 111 ++ 0 i + 0 0 0 0 0 
LD 112 0 0 k 0 0 0 0 0 0 
LD 113 + 0 f+ k 0 0 0 0 0 
LD 114 + 0 5 + 0 0 0 0 0 
O=negative; + =slight in amount; +=moderate in amount; ++=marked in amount. 
mesangial matrix; the epithelial, endothelial, and 
mesangial cells possessed increased numbers of free 
ribosomes, cytosomes, and cytosegresomes, and 
larger amounts of rough endoplasmic reticulum. In 
the four most severely damaged homogratts, some of 
the capillary lumina were narrowed by swollen endo- 
thelial cells. Neutrophile polymorphonulcear leuko- 
cytes were present in the glomerular capillary loops 
of three of the latter transplants. In each of the eight 
kidneys, there were areas in which the epithelial foot 
processes were fused, but this change was only pro- 
nounced in two of the grafts. 
Although the majority of these renal homografts 
showed some vascular damage in the form of sub- 
endothelial collections of hyaline in arteriolar walls 
and fibrous intimal thickening of interlobular 
arteries, in four of the kidneys these changes were 
minor and affected only a few vessels. In only two 
were they at all marked. 
Dense focal collections of mononuclear cells were 
present in seven of the homografts and were fre- 
quent in four of these. Up to 40 per cent of the cells 
had pyroninophilic cytoplasni. In two of the grafts, 
the cytoplasm of some of the infiltrating cells stained 
positively for IgC while others were positive for 
IgM; in three other grafts, only cells that stained for 
IgM were found. Ultrastructurally, some of the cells 
were plasma cells with elaborate rough endoplasmic 
reticulum and others were lymphoid with abundant 
free ribosomes in the cytoplasm but no rough endo- 
plasmic reticulum. 
Future Use of ALG 
It is, of course, too early to predict what effect 
antilymphocyte globulin will have on the long-term 
course after renal homotransplantation or to what 
extent it will influence the development of this field. 
However, two features of the clinical experience re- 
ported above are distinctly encouraging. First, the 
early mortality which has plagued efforts at clinical 
renal homotransplantation has been sharply reduced 
if not virtually eliminated. Secondly, this apparently 
beneficial effect has been possible without prohibi- 
tive toxicity. Anaphylactic reactions were seen, but 
these were surprisingly minor and did not necessitate 
cessation of therapy in most cases. 
Two possible complications of serum nephrotoxic- 
ity which could have defeated the purpose for 
which treatment was intended were proven not to 
have occurred in any of the first eight cases. These 
were direct binding of the horse antibodies with the 
grafted kidney (Masugi nephritis), or secondary in- 
jury to the kidney with entrapped soluble antigen- 
antibody complexes (serum sickness nephritis). The 
absence of horse protein in these biopsies exclude 
both possibilities at least in these cases since the 
heterologous protein in both kinds of experimental 
nephritis is known to remain in renal tissue for many 
months after infliction of the injury and would surely 
have been detectable had it been present. 
Furthermore, the continued good function in the 
first eight cases from two to three months after com- 
pletion of the course of antilymphocyte globulin is an 
additional positive notation, particularly since there 
is reason to believe that any therapy which is of 
valne during the early post-transplant period may 
confer a long-term benefit. This is not because of a 
continuing immunosuppressive effect. Rather, it ap- 
pears to be due to an alteration which leads to a 
state of relative host-graft nonreactivity. This poorly 
understood change, termed "adaptation" by Wood- 
ruff and W o o d r ~ f f , ~ ~  who were the first to show its 
development, is the cornerstone upon which many of 
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the advances in clinical homotransplantation are  
based, since it implies that the maximum need for 
immunoslippression is soon after operation. Later it 
has often been possible to maintain patients for years 
on drug doses no greater or even less than those 
which a t  an earlier time had been quite inadequate 
for control of reje~tion.~"hus, although it could be  
reasoned that upward adjustments of azathioprine 
and especially prednisone dosage might be  required 
at the termination of the four month course of ALG, 
there was good reason to believe that this might not 
be  the case. In point of fact, none of the eight pa- 
tients who have been followed for two to four 
months since their last ALG injection have required 
such adjustments. 
It  would b e  myopic, however, to think that im- 
provements cannot b e  made with ALG therapy. The  
product now being used is a relatively crude extract 
from the serum of horses which conceivably could be  
immunized in a more effective way. I t  has been re- 
marked that the principal precipitin response in the 
patients was to alpha and beta fractions which con- 
tain minor quantities of anti-white-blood-cell anti- 
bodies. Presumably, if these portions were removed 
there would b e  less antigenicity with only slight loss 
of potency. 
In the cases treated until now, the ALG has pri- 
marily been used as a steroid-sparing device. That 
this objective appears to have been met is a sicnifi- 
cant gain since the steroids have contributed heavily 
to post-transplantation morbidity and mortality.6 
Nevertheless, should efforts b e  successful either to 
decrease the antigenicity of the foreign protein or to 
increase its potency, there should b e  no reason why 
ALG could not be used as a primary rather than an 
adjuvant immunosuppressive agent. 
Addendum 
The foregoing acconnt was written in February 1967. 
On August 24, 1967, the results remained essentially the 
same. All patients then alive were still surviving with 
function of the originally transplanted kidney. 
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